Human Anti-HIV-1 gp120 Recombinant Antibody (clone 412d) (CAT#: PABL-142)

Recombinant Human Antibody (412d) is capable of binding to HIV-1 env, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 env mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 env mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 In vitro neutralization by combinations of CD4bs antibodies with CD4i antibodies.

Figure 1 In vitro neutralization by combinations of CD4bs antibodies with CD4i antibodies.

(A) HIV-1 isolates 89.6, ADA, and SG3 were preincubated for 1 h with a fixed total concentration (0.3 μg/ml for 89.6 and ADA and 0.005 μg/ml for SG3) but various ratios of VRC01-E51 mixtures. TZM-bl cells were then added and incubated for 48 h. Infection was measured by the percent luciferase expression in the absence of inhibitor. (B) Experiment similar to that for panel A except that the indicated isolates were preincubated for 1 h with a fixed total concentration (0.3 μg/ml for 89.6 and ADA and 1.0 μg/ml for SA32) but various ratios of VRC01-412d mixtures.

Gardner, M. R., Fellinger, C. H., Prasad, N. R., Zhou, A. S., Kondur, H. R., Joshi, V. R.,... & Farzan, M. (2016). CD4-induced antibodies promote association of the HIV-1 envelope glycoprotein with CD4-binding site antibodies. Journal of virology, JVI-00803.

Figure 2 In vitro neutralization by CD4i antibodies on CD4i-resistant HIV-1 isolates.

Figure 2 In vitro neutralization by CD4i antibodies on CD4i-resistant HIV-1 isolates.

(A) HIV-1 isolates BG505 and ConC were preincubated for 1 h with various concentrations of VRC01, E51, 412d, and 17b. TZM-bl cells were then added and incubated for 48 h. Infection was measured by the percent luciferase expression in the absence of inhibitor. (B) Similar to panel A except that BG505 or ConC was preincubated for 1 h with a fixed total concentration (0.033 μg/ml for BG505 or 0.045 μg/ml for ConC) but various ratios of VRC01-E51 mixtures. (C) Similar to panel A except that BG505 or ConC was preincubated for 1 h with a fixed total concentration (0.033 μg/ml for BG505 or 0.045 μg/ml for ConC) but various ratios of VRC01-412d mixtures.

Gardner, M. R., Fellinger, C. H., Prasad, N. R., Zhou, A. S., Kondur, H. R., Joshi, V. R.,... & Farzan, M. (2016). CD4-induced antibodies promote association of the HIV-1 envelope glycoprotein with CD4-binding site antibodies. Journal of virology, JVI-00803.

Figure 3 In vitro neutralization curves of mixtures of VRC01 or b12 with E51, 412d, or 2G12.

Figure 3 In vitro neutralization curves of mixtures of VRC01 or b12 with E51, 412d, or 2G12.

The experiment was similar to that described for Fig. 1 except that HIV-1 isolates 89.6, ADA, SG3, and SA32 was preincubated with various concentrations of indicated antibodies or mixture of antibodies. The dashed lines indicate the fixed concentration used for Fig. 1A and B. For the 89.6 and ADA neutralization curves, 50:50 mixtures of VRC01 and E51, VRC01 and 412d, b12 and E51, and VRC01 and 2G12 were used. For the SG3 neutralization curves, 25:75 mixtures of VRC01 and E51, b12 and E51, and VRC01 and 2G12 were used, while a 75:25 mixture of VRC01 and 412d was used (to accommodate for the lack of potency of 412d on SG3). For the SA32 neutralization curves, a 40:60 ratio of VRC01 and E51 was used, while 60:40 ratios of VRC01 and 412d, b12 and 412d, and VRC01 and 2G12 were used.

Gardner, M. R., Fellinger, C. H., Prasad, N. R., Zhou, A. S., Kondur, H. R., Joshi, V. R.,... & Farzan, M. (2016). CD4-induced antibodies promote association of the HIV-1 envelope glycoprotein with CD4-binding site antibodies. Journal of virology, JVI-00803.

Figure 4 Promotion of CD4bs antibody association with trimeric Env by CD4i antibodies and CCR5mim2-Ig.

Figure 4 Promotion of CD4bs antibody association with trimeric Env by CD4i antibodies and CCR5mim2-Ig.

(A) The cells were preincubated with E51 at serially diluted concentrations starting at 50 μg/ml. Cells were washed and then incubated with 0.01 μg/ml of the indicated CD4bs antibody or CD4-Ig. Analysis was performed as for Fig. 4 except that MFI data were normalized to the value of each antibody or CD4-Ig binding without E51 preincubation. (B) Experiment similar to that for panel A except that cells were preincubated with 50 μg/ml of 412d, 17b, or CCR5mim2-Ig. Note that the scale of the y axes varies between graphs.

Gardner, M. R., Fellinger, C. H., Prasad, N. R., Zhou, A. S., Kondur, H. R., Joshi, V. R.,... & Farzan, M. (2016). CD4-induced antibodies promote association of the HIV-1 envelope glycoprotein with CD4-binding site antibodies. Journal of virology, JVI-00803.

Figure 5 The precipitation of the indicated full-length gp120 glycoproteins by the 412d antibody in the presence of 10 g/ml sCD4 is shown in the top panel. The ability of the envelope glycoproteins to bind Cf2Th-CCR5 cells after incubation with 10 g/ml sCD4 is shown in the bottom panel.

Figure 5 The precipitation of the indicated full-length gp120 glycoproteins by the 412d antibody in the presence of 10 g/ml sCD4 is shown in the top panel. The ability of the envelope glycoproteins to bind Cf2Th-CCR5 cells after incubation with 10 g/ml sCD4 is shown in the bottom panel.

Xiang, S. H., Farzan, M., Si, Z., Madani, N., Wang, L., Rosenberg, E.,... & Sodroski, J. (2005). Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. Journal of virology, 79(10), 6068-6077.

Figure 6 Recombinant luciferase-expressing viruses with the wild-type HXBc2 or HXBc2 NM/DI envelope glycoproteins were used to infect Cf2Th-CD4/CXCR4 cells. In some cases, viruses were first incubated with the 412d antibody. Luciferase activity in the target cells is shown.

Figure 6 Recombinant luciferase-expressing viruses with the wild-type HXBc2 or HXBc2 NM/DI envelope glycoproteins were used to infect Cf2Th-CD4/CXCR4 cells. In some cases, viruses were first incubated with the 412d antibody. Luciferase activity in the target cells is shown.

Xiang, S. H., Farzan, M., Si, Z., Madani, N., Wang, L., Rosenberg, E.,... & Sodroski, J. (2005). Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. Journal of virology, 79(10), 6068-6077.

Figure 7 Coexpression of Env and CD4 also induces conformational changes in Env that enhance CD4i epitopes (17b and 412D)

Figure 7 Coexpression of Env and CD4 also induces conformational changes in Env that enhance CD4i epitopes (17b and 412D)

Veillette, M., Désormeaux, A., Medjahed, H., Gharsallah, N. E., Coutu, M., Baalwa, J.,... & Haynes, B. F. (2014). Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity.Journal of virology, 88(5), 2633-2644.


Specifications

  • Host Species
  • Human
  • Type
  • Human IgG
  • Species Reactivity
  • HIV-1
  • Clone
  • 412d
  • Applications
  • Neut, WB, ELISA, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The antibody was validated for Neut. For details, refer to published data.

Target

  • Alternative Names
  • ENV; gp160; envelope glycoprotein; Envelope surface glycoprotein gp160; precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 412d"

See other products for "HIV-1 gp120"

Single-domain Antibody

Chimeric Antibody

CAT Product Name Application Type
MRO-135LC Anti-HIV-1 gp120 Recombinant Antibody (CAG1-51-4) ELISA, WB, Neut Chimeric antibody (mouse/human)
MRO-135LC-S(P) Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)
MRO-135LC-F(E) Anti-HIV-1 gp120 Recombinant Antibody Fab Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-4220 Rabbit Anti-HIV-1 gp120 Recombinant Antibody (clone SI299DS) WB, ELISA Rabbit IgG

Humanized Antibody

CAT Product Name Application Type
PABX-101-S(P) Human Anti-HIV-1 gp120 Recombinant Antibody (clone PG9); scFv Fragment WB, ELISA, FuncS Human scFv

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-142. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare